Short Interest in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Declines By 36.9%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 1,250,000 shares, a decline of 36.9% from the February 28th total of 1,980,000 shares. Currently, 2.6% of the shares of the stock are short sold. Based on an average daily volume of 2,640,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Investors Weigh In On Cardio Diagnostics

Several large investors have recently modified their holdings of the stock. Two Sigma Securities LLC acquired a new position in shares of Cardio Diagnostics in the 4th quarter valued at $48,000. Jane Street Group LLC acquired a new position in Cardio Diagnostics in the 4th quarter worth approximately $103,000. Millennium Management LLC purchased a new position in shares of Cardio Diagnostics during the fourth quarter valued at $236,000. Finally, Geode Capital Management LLC lifted its stake in Cardio Diagnostics by 97.6% in the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock worth $334,000 after acquiring an additional 179,978 shares in the last quarter. 8.06% of the stock is owned by institutional investors.

Cardio Diagnostics Stock Down 13.4 %

CDIO stock traded down $0.05 on Monday, hitting $0.33. 1,096,507 shares of the company’s stock traded hands, compared to its average volume of 2,529,280. Cardio Diagnostics has a 1-year low of $0.19 and a 1-year high of $1.77. The stock has a fifty day moving average of $0.48 and a 200-day moving average of $0.48.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.